Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 16;8:80. doi: 10.1038/s41421-022-00433-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Jurkat cells were transduced with mIL-5-anchored CCAR comprising a mouse IL-5 linked to human CD28 costimulatory and CD3ζ signaling domains (m.IL-5-h.28z). Flow cytometry analysis of CD69 expression on mIL-5-anchored CCAR-Jurkat cells after coculture with target cells (U2OS cells) for 24 h. One-way ANOVA, ^****P < 0.0001. b Jurkat cells were transduced with hIL-5-CCAR comprising a human IL-5 linked to human CD28 costimulatory and CD3ζ signaling domains (h.IL-5-h.28z). Flow cytometry analysis of CD69 expression on hIL-5-anchored CCAR-Jurkat cells after coculture with target cells for 24 h. Dunn’s Kruskal-Wallis test. c Primary T cells from BALB/c mice were transduced with mIL-5-CCAR comprising a mouse IL-5 linked to mouse CD28 costimulatory and CD3ζ signaling domains (m.IL-5-m.28z). Cytotoxic activity of mIL-5-anchored CCAR-T cells against mIL-5Rα⁺ U2OS cells. Two-way ANOVA, ^****P < 0.0001, ^*P < 0.05. d Flow cytometry analysis showing the proportion of primary mIL-5Rα⁺ cells derived from bone marrow after treating with mIL-5-anchored CCAR-T cells or UTD-T cells at a CCAR-T to target ratio of 6:1 in vitro for 8 h. UTD-T, un-transduced T cells. Two-tailed t-test, ^****P < 0.0001. e Normalized cell death of primary mIL-5Rα⁺ cells or mIL-5Rα^– cells after treating with mIL-5-anchored CCAR-T cells or UTD-T cells. Differences between mIL-5-anchored CCAR-T cells-treated and UTD-T cells-treated group were examined by two-way ANOVA, ^****P < 0.0001. f Timeline of Eos differentiation induction, mIL-5-anchored CCAR-T cell administration, and flow cytometry analysis of Eos. The mIL-5-anchored CCAR-T cells were administrated at a CCAR-T/Target ratio of 3:1. Eos, eosinophil. g Flow cytometry plots showing the proportion of BM-derived Eos after treating with mIL-5-anchored CCAR-T cells or not. BM, bone marrow. Two-tailed t-test, ^***P < 0.001. h Histogram of the cell count of BM-derived Eos. Brown-Forsythe and Welch ANOVA, ^*P < 0.05.